Return to CG62 Overview

Ante-natal care [CG62]

Measuring the use of this guidance

Recommendation: 1.1.1.5

At each antenatal appointment, healthcare professionals should offer consistent information and clear explanations, and should provide pregnant women with an opportunity to discuss issues and ask questions.

What was measured: Percentage of women who answered 'yes' to the question 'During your antenatal check-ups, were you given enough time to ask questions or discuss your pregnancy?'
Data collection end: February 2013
74%
Data collection end: February 2015
75%
Area covered: England
Source: Care Quality Commission. Survey of women's experiences of maternity care.


Recommendation: 1.3.2.4

New All women should be informed at the booking appointment about the importance for their own and their baby’s health of maintaining adequate vitamin D stores during pregnancy and whilst breastfeeding. In order to achieve this, women may choose to take 10 micrograms of vitamin D per day, as found in the Healthy Start multivitamin supplement. Particular care should be taken to enquire as to whether women at greatest risk are following advice to take this daily supplement. These include: • women of South Asian, African, Caribbean or Middle Eastern family origin • women who have limited exposure to sunlight, such as women who are predominantly housebound, or usually remain covered when outdoors • women who eat a diet particularly low in vitamin D, such as • women who consume no oily fish, eggs, meat, vitamin D-fortified margarine or breakfast cereal • women with a pre-pregnancy body mass index above 30 kgm2

What was measured: Proportion of women overall who took vitamin D supplementation
Data collection end: April 2011
52%
Area covered: Local
Source: Galea P, et al. (2012) Antenatal vitamin D supplementation in a multicultural population in a West London Hospital. British Journal of Obstetrics and Gynaecology. Vol 119, p64

What was measured: Women with BMI > 30 kg/m2 who were taking vitamin D supplements
Data collection end: April 2011
37%
Area covered: Local
Source: Galea P, et al. (2012) Antenatal vitamin D supplementation in a multicultural population in a West London Hospital. British Journal of Obstetrics and Gynaecology. Vol 119, p64


Recommendation: 1.3.10.4

Monitor smoking status and offer smoking cessation advice, encouragement and support throughout the pregnancy and beyond.

What was measured: Public Health Outcomes Framework indicator 2.03: Proportion of women who smoke at time of delivery.
Data collection end: March 2011
13.5%
Data collection end: March 2012
13.2%
Data collection end: March 2013
12.7%
Data collection end: March 2014
12%
Data collection end: March 2015
11.4%
Area covered: England
Source: Health and Social Care Information Centre. Statistics on Women's Smoking Status at Time of Delivery, England.

What was measured: Public Health Outcomes Framework indicator 2.03: Proportion of women who smoke at time of delivery.
Data collection end: March 2017
10.5%
Number that met the criteria: 65023 / 619234
Area covered: England
Source: Health and Social Care Information Centre. Statistics on Women's Smoking Status at Time of Delivery, England.


Recommendation: 1.6.2.2

It is recommended that routine antenatal anti‑D prophylaxis is offered to all non‑sensitised pregnant women who are rhesus D‑negative.

What was measured: Proportion of pregnant RhD-negative women who received anti-D prophylaxis during the antenatal period.
Data collection end: December 2012
95%
Area covered: Local
Source: Myint HHG (2015) Audit of use of anti-d in rhesus negative pregnant women at noble's hospital, isle of man. International Journal of Gynecology and Obstetrics Conference: October


Recommendation: 1.6.3.3

New Screening for sickle cell diseases and thalassaemias should be offered to all women as early as possible in pregnancy (ideally by 10 weeks). The type of screening depends upon the prevalence and can be carried out in either primary or secondary care.

What was measured: Public Health Outcomes Framework indicator 2.21iii: The percentage of pregnant women eligible for antenatal sickle cell and thalassaemia screening for whom a conclusive screening result is available at the day of report.
Data collection end: March 2014
98.87%
Data collection end: March 2015
98.86%
Area covered: England
Source: Public Health England. Public Health Outcomes Framework

What was measured: The proportion of women having antenatal sickle cell and thalassaemia screening for whom a conclusive screening result is available by 10 weeks’ gestation.
Data collection end: December 2014
50.4%
Number that met the criteria: 338769 / 672797
Data collection end: December 2015
51.2%
Number that met the criteria: 334423 / 652702
Data collection end: December 2016
51.8%
Number that met the criteria: 352742 / 680558
Area covered: England
Source: Public Health England: National Screening Programme Key Performance Indicators.

What was measured: The proportion of women having antenatal sickle cell and thalassaemia screening for whom a conclusive screening result is available by 10 weeks’ gestation.
Data collection end: December 2014
50.4%
Number that met the criteria: 338769 / 672797
Data collection end: December 2015
51.2%
Number that met the criteria: 334423 / 652702
Data collection end: December 2016
51.8%
Number that met the criteria: 352742 / 680558
Area covered: England
Source: Public Health England: National Screening Programme Key Performance Indicators.



 Return to CG62 Overview